Clinical trials: Epilepsy, Partial
Epilepsy, Partial
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is…
- Trial name
- NCT00150709
- Testing
- Levetiracetam
- Volunteers
- 223 people
- Sponsor
- UCB Pharma
Epilepsy
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the…
- Trial name
- NCT00530855
- Testing
- Lacosamide
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 322 people
- Sponsor
- UCB Pharma
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Partial Epilepsy
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT07594158
- Testing
- Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Epilepsy
Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
To determine the efficacy and safety of adjunctive open label Zonegran treatment in patients with refractory partial seizures.
- Trial name
- NCT00215592
- Testing
- Zonegran
- Where
- 33 sites in Austria, Denmark and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Eisai Limited
Epilepsy With Partial On-set Seizures
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
- Trial name
- NCT03116828
- Testing
- Eslicarbazepine acetate
- Where
- 55 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Sumitomo Pharma America, Inc.
Focal Epilepsy
A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
- Trial name
- NCT06612775
- Testing
- Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 20mg group
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
An Extended Access Program (EAP) for Perampanel
The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time…
- Trial name
- NCT02307578
- Testing
- Perampanel
- Where
- 27 sites in Belgium, Chile and 8 more
- Sponsor
- Eisai Inc.
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.